Parallax Volatility Advisers’s Alnylam Pharmaceuticals ALNY Stock Holding History

Parallax Volatility Advisers’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-31,700	Closed	-$7.46M	–	1537
2024 Q4	$7.46M	Buy	31,700 +29,200	+1,168%	+$7.68M	0.01%	671
2024 Q3	$688K	Buy	+2,500	New	+$651K	﹤0.01%	1450
2024 Q2	–	Sell	-2,800	Closed	-$418K	–	1969
2024 Q1	$418K	Buy	+2,800	New	+$467K	﹤0.01%	1453
2023 Q1	–	Sell	-13,300	Closed	-$3.16M	–	2686
2022 Q4	$3.16M	Buy	+13,300	New	+$2.84M	﹤0.01%	1221
2020 Q4	–	Sell	-89,400	Closed	-$13M	–	2273
2020 Q3	$13M	Buy	89,400 +16,300	+22%	+$2.32M	0.01%	885
2020 Q2	$10.8M	Buy	73,100 +67,400	+1,182%	+$9.09M	0.01%	745
2020 Q1	$623K	Buy	+5,700	New	+$658K	﹤0.01%	1638
2018 Q4	–	Sell	-21,500	Closed	-$1.88M	–	2872
2018 Q3	$1.88M	Buy	+21,500	New	+$2.16M	﹤0.01%	1044
2017 Q3	–	Sell	-15,000	Closed	-$1.2M	–	2039
2017 Q2	$1.2M	Buy	+15,000	New	+$959K	﹤0.01%	983

Other funds holding ALNY

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Parallax Volatility Advisers's ALNY Position: Q1 2025 in Review

Parallax Volatility Advisers sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2025, closing a stake of 23,161 shares — an estimated $5.45M sold.

Parallax Volatility Advisers first reported a position in ALNY in Q2 2015 and held it in 17 quarters. The position peaked at $7.3M in Q3 2024. 627 funds tracked by Wall St. Rank hold ALNY as of Q1 2025.

Parallax Volatility Advisers reported no remaining Alnylam Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Parallax Volatility Advisers sold 23,161 Alnylam Pharmaceuticals shares in Q1 2025, an estimated $5.45M.
Parallax Volatility Advisers first reported a position in Alnylam Pharmaceuticals in Q2 2015 and held it in 17 quarters.
Parallax Volatility Advisers's Alnylam Pharmaceuticals position peaked at $7.3M in Q3 2024.
627 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2025.

Based on Parallax Volatility Advisers's 13F filing for Q1 2025, filed 15 May 2025.